NCT01987453 - Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

HCV Infection

Interventions

DRUG

LDV/SOF

Tablet(s) administered orally once daily

DRUG

RBV

"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."

Trial Locations (43)

2050

Camperdown

10029

New York

11030

Manhasset

13903

Binghamton

19104

Philadelphia

20009

Washington D.C.

21229

Baltimore

23226

Richmond

23502

Norfolk

27103

Winston-Salem

28801

Asheville

30060

Marietta

32256

Jacksonville

32610

Gainesville

32803

Orlando

33136

Miami

33414

Wellington

38138

Germantown

42101

Bowling Green

46237

Indianapolis

55414

Minneapolis

60515

Downers Grove

60611

Chicago

64131

Kansas City

70809

Baton Rouge

78215

San Antonio

80045

Aurora

87131

Albuquerque

90027

Los Angeles

90036

Los Angeles

90069

Los Angeles

90210

Beverly Hills

92037

La Jolla

92056

Oceanside

92103

San Diego

92110

Clichy

94115

San Francisco

98111

Seattle

02215

Boston

01105

Springfield

08844

Hillsborough

00927

San Juan

08028

Barcelona